湖南景峰医药股份有限公司 2025 年半年度报告全文 湖南景峰医药股份有限公司 公司的法定代表人 刘树林 二、联系人和联系方式 董事会秘书 证券事务代表 姓名 张莉（代行） 陈敏 湖南省常德经济技术开发区樟木桥街 湖南省常德经济技术开发区樟木桥街 联系地址 道双岗社区桃林路 661 号（双创大 道双岗社区桃林路 661 号（双创大 厦） 厦） 电话 0736-7320908 0736-7320908 传真 0736-7320908 0736-7320908 电子信箱 ir@jfzhiyao.com ir@jfzhiyao.com 三、其他情况 公司注册地址、公司办公地址及其邮政编码、公司网址、电子信箱等在报告期是否变化 □适用 ?不适用 公司注册地址、公司办公地址及其邮政编码、公司网址、电子信箱等在报告期无变化，具体可参见 2024 年年报。 信息披露及备置地点在报告期是否变化 □适用 ?不适用 湖南景峰医药股份有限公司 2025 年半年度报告全 湖南景峰医药股份有限公司 2025 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述 ...

Group 1 - The core point of the article highlights that ST Jinfeng's shareholders have a pledge ratio of 12.56% of the total share capital, ranking 745th in the market as of August 8 [1] - ST Jinfeng's shareholders have pledged a total of 111 million shares across 11 transactions, with a total market value of 663 million yuan [1] - The company, Hunan Jinfeng Pharmaceutical Co., Ltd., specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique or included in national medical insurance [1] Group 2 - Over the past year, ST Jinfeng's stock has increased by 133.46%, indicating significant growth in its market performance [1]

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with a diverse product line including unique national insurance drugs and various injectable solutions [2]. Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.9 million yuan, representing a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of August 4, ST Jingfeng's stock closed at 5.94 yuan, down 1.16%, with a rolling price-to-earnings (PE) ratio of 36.92 times. The company's total market capitalization is 5.226 billion yuan [1]. - In comparison to the chemical pharmaceutical industry, which has an average PE ratio of 65.00 times and a median of 35.58 times, ST Jingfeng ranks 93rd in the industry [1][3]. Capital Flow - On August 4, the company experienced a net outflow of 3.8761 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 37.949 million yuan [1].

Group 1 - The core point of the article highlights that ST Jingfeng's shareholders have a pledge ratio of 12.63% of the total share capital, ranking 749th in the market as of the last trading day on August 1 [1] - ST Jingfeng's shareholders have pledged a total of 111 million shares across 11 transactions, with a total market value of 668 million yuan [1] - The company specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injection solutions and capsules, many of which are unique in the national market and included in the national medical insurance [1] Group 2 - The stock price of ST Jingfeng has increased by 199.00% over the past year [1] - The chairman of the company is Zhang Li [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of ST Jingfeng, indicating a current stock price of 5.88 yuan with a PE ratio of 36.55 times, which is lower than the industry average of 61.55 times [1][3] - The company has a total market capitalization of 5.173 billion yuan, ranking 94th in the chemical pharmaceutical industry based on PE ratio [1][3] - Recent funding trends show a net inflow of 6.0358 million yuan on July 25, but a total outflow of 12.6988 million yuan over the past five days [1] Group 2 - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules, many of which are unique or under national medical insurance [2] - The company is actively expanding its product line and has several products that have received clinical approval or are in clinical research stages [2]

7月24日，ST景峰今日收盘5.74元，下跌1.03%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到35.68倍，总市值50.50亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13ST景峰35.6833.1672.2450.50亿行业平均 62.3759.936.37149.81亿行业中值34.2433.912.8773.44亿1新和成9.9811.702.24686.60亿2浙江医药 10.0012.581.32145.98亿3吉林敖东11.9914.870.78230.69亿4华润双鹤12.5112.461.86202.78亿5国药现代 14.5613.941.11151.02亿6华特达因14.5714.962.4977.12亿7国邦医药14.8615.161.44118.53亿8哈药股份 15.2216.101.82101.24亿9健康元16.2816.231.54225.02亿10九典制药17.3817.393.4389.09亿11普洛药业 17.6517.732.61182.80亿12诚意药业18.2519.443.0139.01亿 来源：金融界 股东方面，截至202 ...

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique or under national medical insurance categories [2]. Financial Performance - In Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, reflecting a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of July 8, 2023, ST Jingfeng's stock closed at 5.99 yuan, with a rolling price-to-earnings (PE) ratio of 37.24 times, compared to the industry average PE of 54.20 times and a median of 32.89 times, placing the company at the 95th position within its industry [1][3]. - The total market capitalization of ST Jingfeng is 5.27 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders for ST Jingfeng was 34,311, a decrease of 6,228 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with a diverse product line including unique national insurance drugs [2] Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.9 million yuan, a significant decline of 960.04% compared to the previous year [3] - The gross profit margin for the company stands at 66.62% [3] Market Position - As of July 3, 2023, the company's stock closed at 5.87 yuan, down 1.34%, with a rolling price-to-earnings (PE) ratio of 36.49 times, compared to the industry average PE of 54.72 times and a median of 33.17 times, placing the company at the 95th position in the industry [1][3] - The total market capitalization of the company is 5.164 billion yuan [1] Shareholding Structure - As of the Q1 2025 report, two institutions hold shares in the company, with a total of 12,476.40 million shares valued at 558 million yuan [1]

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique in the market and covered by national medical insurance [2]. Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, representing a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of July 1, ST Jingfeng's stock closed at 6.06 yuan, reflecting an increase of 1.68%. The rolling price-to-earnings (PE) ratio reached 37.67, with a total market capitalization of 5.33 billion yuan. In comparison, the average PE ratio for the chemical pharmaceutical industry is 54.81, and the industry median is 32.58, placing ST Jingfeng at the 96th position within the industry [1][3]. Capital Flow - On July 1, ST Jingfeng experienced a net inflow of 9.70 million yuan in principal funds, although the overall trend over the past five days showed a net outflow of 2.44 million yuan [1].

Group 1 - The core business of the company is the research, manufacturing, and sales of pharmaceutical products, with a focus on various injection solutions and capsules, many of which are unique in the market and covered by national health insurance [2] - The company reported a revenue of 1.00 billion yuan for Q1 2025, showing a year-on-year decrease of 0.46%, and a net profit loss of approximately 11.90 million yuan, reflecting a significant year-on-year decline of 960.04% [3] - The company's gross profit margin stands at 66.62%, indicating a relatively high profitability despite the revenue decline [3] Group 2 - As of June 24, the company's stock price closed at 5.8 yuan, with a rolling price-to-earnings (PE) ratio of 36.05, which is lower than the industry average PE of 54.23 [1][3] - The total market capitalization of the company is approximately 51.03 billion yuan, ranking it 96th in the chemical pharmaceutical industry based on PE ratio [1][3] - Over the past five days, the company experienced a net outflow of main funds amounting to 8.51 million yuan, indicating a trend of capital withdrawal [1]